Slide 1: Results Presentation for the Full Year Ended 30 June 2020
For personal use only For immediate release 19 August 2020 RESULTS PRESENTATION FOR THE FULL YEAR ENDED 30 JUNE 2020 Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY) Please find attached the slides for the presentation on the full year results that will be given by the Chief Executive Officer and C
Slide 2: CSL Limited 2020 Full Year Results
For personal use only CSL Limited 2020 Full Year Results 19th August, 2020 Paul Perreault David Lamont CEO and MD CFO
Slide 3: Forward Looking Statements
For personal use only FORWARD LOOKING STATEMENTS The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in resear
Slide 4: A strong year for CSL
A strong year for CSL FY20 Revenue Performance1 with revenue up 9%1 A strong year for CSL For personal use only and profit after tax up 17%1 reflecting: • Strong growth in CSL Behring Seqirus immunoglobulin portfolio • PRIVIGEN® +20% • Seasonal influenza sales +21% • Successful evolution of • HIZENT
Slide 5: CSL Behring Sales FY20
CSL Behring Sales FY20 For personal use only Sales Change1 Therapy $m % Immunoglobulins 4,014 22% 19% - IVIG 2,699 16% - SCIG 1,315 34% Albumin 640 (36%) 29% Haemophilia 1,122 8% - Recombinants 659 18% US$7.7B - Plasma 463 (3%) 16% Specialty 1,697 10% 8% 13% - Peri-Operative Bleeding 788 10% - Other
Slide 6: Immunoglobulins
Immunoglobulins Sales up 22%1 For personal use only Market • Global Ig demand remains strong Market Demand Drivers 20% growth1 34% growth1 • Increased disease • CIDP indication in the US and • Clear market leader awareness & improved EU diagnosis • New patient starts in • Expansion of SID usage PID
Slide 7: Albumin
Albumin Sales down 36%1 For personal use only • Volume up 16% globally, excluding China: Transitioned to Good Supply Practices − Europe up 24% (GSP) license in China − North America up 6% • Successful transition of − Emerging markets, excluding China, up 28% business model − Pricing pressure in some
Slide 8: Haemophilia
Haemophilia Sales up 8%1 For personal use only Plasma Derived Coagulation Factors • 25% growth1 • 21% growth1 • Modest growth in HUMATE® /HAEMATE® • Differentiated product • Double digit growth in (vWF) nearly all launched markets • Strong growth in US, Japan • pdVIII competitive and Switzerland • P
Slide 9: Specialty Products
Specialty Products Sales increased by 10%1 For personal use only • 12%1 growth • 12%1 growth • Deeper penetration into • Capacity expansion broad hospital • New launches in EU segment and Canada 10% 9% US$1,697m • 10%1 growth • Maintained global leadership position • 20%1 growth • 5% growth • Supply
Slide 10: Plasma Collections
Plasma Collections For personal use only Continue to grow plasma collection network 40 new centres 277 centres: Plan to open opened in the ✓ 261 United States 20 - 30 United States new centres ✓ 8 Germany in FY21 ✓ 3 Hungary ALL CENTERS ✓ 5 China REMAIN OPEN 9
Slide 11: COVID-19 Impact on Plasma Collections
Protecting Plasma Collections Staff and COVID-19 Impact Donors For personal use only Challenge Mitigation Actions • Pre-assessment of • Plasma collections • Collection centres designated ‘essential potential donors adversely impacted critical infrastructure’ • Re-direction of donors to sister center
Slide 12: Seqirus Revenue FY20
Seqirus Revenue FY20 Revenue up 11%1 For personal use only Sales Change1 Therapy $m % QIV 542 27% Seasonal 57% TIV 31 (53%) Influenza 19% vaccines Adjuvanted 379 30% +21% Other / In-licence 184 (11%) Total Product Sales 1,136 14% Pandemic 145 11% US$1.3B Other Income 16 (64%) 18% 11% Total Revenue 1
Slide 13: Seqirus Operating Highlights and Looking Forward
Seqirus For personal use only Operating Looking Highlights Forward • Strong result driven by • COVID-19 driving ongoing product demand: differentiation ─ Increased supply • Critical operations maintained into the US of up to during COVID pandemic ~60m doses for NH20/21 • Real world evidence continue
Slide 14: Seqirus Operating Highlights and Looking Forward
Seqirus For personal use only Operating Looking Highlights Forward FLUCELVAX® FLUCELVAX®: • All strains manufactured using cell- • Expanded paediatric specific seed for NH 2019/20 season in US and EU 2021 • aQIVc to commence • Launched in EU (9 years+) clinical trials NH20/21 FLUAD® FLUAD QIV® : • O
Slide 15: R&D Highlights
R&D Highlights For personal use only Immunology Hematology Transplant • HIZENTRA® Phase III DM study initiated • CSL200 in SCD Phase I study initiated • AAT for prevention of GvHD Phase III study enrolment into Cohort 2 completed • PRIVIGEN® Phase II SSc study initiated • CSL889 Hemopexin Phase I SC
Slide 16: COVID-19 Response Update
PREVENTION TREATMENT For personal use only Therapeutic Vaccines Hyperimmunes Monoclonal Options Polyclonal Antibodies Antibodies COVID-19 Collaborators • University of • Hyperimmunes • Academic clinical Queensland researchers Response • Coalition for ‐ Alliance with Takeda and others Epidemic ‐ Aust
Slide 17: COVID-19 Summary
PEOPLE COVID-19 • Employees encouraged and supported to work remotely • Flexible and robust IT systems facilitate ongoing productivity • Development of strict protocols to ensure the safety of our employees and donors Summary For personal use only INNOVATION • Focussed response leveraging the Compan
Slide 18: Financials
. For personal use only Financials David Lamont CFO 17
Slide 19: Financial Highlights
Financial Highlights Net Profit After Tax For personal use only $2,247m +17% @CC1 GSP China Transition @CC1 FX$144m • Albumin sales reduction in line with guidance • Profit effect in line with historical CSL Behring margin +10% reported Other Income • One-off $30m benefit New lease standard • Balanc
Slide 20: Financial Highlights: CSL Group
Financial Highlights CSL Group For personal use only Full year ended June FY19 FY20 FY20 Change 1 US$ Millions Reported Reported at CC % Total Revenue 8,539 9,151 9,295 9%1 Gross Profit 4,777 5,226 5,338 12%1 GP margin 56.0% 57.1% 57.4% EBIT 2,504 2,717 2,877 15%1 EBIT margin 29.3% 29.7% 31.0% NPAT
Slide 21: Financial Highlights: Segments
Financial Highlights Segments For personal use only CSL Behring Seqirus US$ FY19 FY20 Change US$ FY19 FY20 Change 1 1 Millions Reported Reported % at CC Millions Reported Reported % at CC Sales 7,187 7,661 8% Sales 1,018 1,136 14% Other Other 156 193 24% 178 161 (7%) Revenue Revenue Total Total 7,34
Slide 22: Financial Highlights: Reported Expenses
Financial Highlights Reported Expenses For personal use only 1 R&D FY20 Change @ CC • CSL112 phase III trial $m $m % • CSL200 SCD gene therapy trial Research & 922 101 12 initiated Development • COVID-19 response Sales & Marketing 896 39 5 Finance (Net) • AASB16 adoption - $26m General & Admin 692 4
Slide 23: Inventory Management
Inventory Management1 Flexibility in the supply chain For personal use only $M Key Insights • Continue to produce for demand • Inventory as a percentage of revenue steady • Seqirus inventory mix impacted by strain notification 1 Reported numbers 22
Slide 24: Capital Expenditure
Capital Expenditure1 Investment to support demand For personal use only $M Capex $B Sales Key Projects • Significant new manufacturing capacity • Additional plasma collection centers • ERP systems completed • Lengnau facility − Thermo Fisher lease − Accelerates optimisation of facility capability •
Slide 25: Key Capital Projects
Key Capital Projects Completion Timeline For personal use only FY20 FY21 FY22 FY23 FY24 FY25 ERP Systems Tech Enterprise Process Management Kankakee Marburg Base Frac Broadmeadows Other Base Frac Modules Bern IG Bulk & IG Modules Finishing Berinert / C1 Precipitate Capacity Increase Lengnau Other Pl
Slide 26: Outlook for FY21
Outlook for FY211 For personal use only Demand • Continued strong demand for plasma and recombinant products • Seqirus’ product differentiation and COVID-19 expected to drive strong demand for influenza vaccines • Albumin sales to normalize following GSP transition Plasma Collections FY211 Outlook •
Slide 27: CSL Contacts
For personal use only CSL Contacts Mark Dehring VP Investor Relations +61 3 9389 3407 mark.dehring@csl.com.au Bernard Ronchi Senior Manager, Investor Relations +61 3 9389 3470 bernard.ronchi@csl.com.au Stephen McKeon Associate Director, Investor Relations +61 3 9389 6798 stephen.mckeon@cs
Slide 28: CSL Strategy and Values
CSL Strategy and Values For personal use only Strategic Overview Patient Superior Innovation Integrity Collaboration Core Focus Performance Values We deliver on We turn innovative We walk the talk We are stronger We take pride in our promise thinking into together our results to patients solutions 2
Slide 29: Notes
Notes For personal use only (#) Constant currency removes the impact of Summary NPAT Reported net profit after tax $2,102.5m exchange rate movements to facilitate Translation currency effect (a) $ (1.0m) comparability of operational performance for the Transaction currency effect (b) $ 60.1m Group.